Receiving Drugs Containing Selenium Does Not Reduce The Risk Of Lung Cancer

Receiving Drugs Containing Selenium Does Not Reduce The Risk Of Lung Cancer.
Taking the accepted mineral addendum selenium doesn't decrease the likelihood of lung cancer recurrence, a new study reveals. Lead author Dr Daniel D Karp, a professor in the area of thoracic head and neck medical oncology at the University of Texas MD Anderson Cancer Center, is scheduled to tip the finding Saturday at the American Society of Clinical Oncology annual meeting, in Chicago. "Several epidemiological and brute studies have long-suggested a connection between deficiency of selenium and cancer development," said Karp in a message release.

So "Interest and research escalated in the late 1990s after a skin cancer and selenium study, published in 1996, found no further against the skin cancer, but did suggest an approximate 30 percent reduction of prostate and lung cancers. Our lung cancer fact-finding and another major study for the prevention of prostate cancer evolved from that finding".